Apply Now
Dr. Fares Al-Ejeh
Senior Scientist
Educational Qualifications
Bachelor of Biotech (Honours)
Ph.D. (Cancer Biology)
Entity
Qatar Biomedical Research Institute
Division
Translational Oncology Research Center
Biography
Associate Professor Fares Al-Ejeh was awarded his Bachelor of Biotechnology degree, and his PhD from the University of Wollongong (NSW, Australia). His first post-doctoral position was industry-funded by Oncaidia Ltd at the Royal Adelaide Hospital/Hanson Institute. .
After five years in industry-oriented research, Dr. Al-Ejeh started his academic career at one of Australia's largest research institutes, the QIMR Berghofer Medical Research Institute. At QIMR, he established his own group, Personalised Medicine, in 2015. His track record includes two granted patents on Apomab and five submitted patent applications undergoing evaluation. He has more than 50 peer-reviewed publications focusing on cancer diagnostics and therapeutics with focus on translational medical research.
Dr. Al-Ejeh has contributed as a keynote speaker at several conferences and as a member of several panels for grant reviews in Australia and internationally. He is an Associate Member of the Australian Academy of Health and Medical Sciences (AAHMS) and an adjunct Associate Professor at the Faculty of Medicine, University of Queensland, Australia in recognition of his teaching and supervision of postgraduate students.
Bachelor of Biotech (Honours)
University of Wollongong (NSW/Australia)
2001
Ph.D. (Cancer Biology)
University of Wollongong (NSW/Australia)
2005
- Personalized/Precision Oncology
- Multi-omics
- Novel Biomarkers and Drug Targets
- Breast Cancer
Senior Scientist
Qatar Biomedical Research Institute/HBKU, Translational Oncology Research Center. Doha, Qatar.
2020 - present
Team Head (Faculty) and Senior Research Fellow
QIMR Berghhofer Medical Research Institute. Brisbane, Australia
2010 - 2019
Senior Researcher and Chief Scientific Officer
Oncaidia Ltd. and the Royal Adelaide Hospital, Hanson Institute. Adelaide, Australia
2005 - 2009
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications. 2022; 13, 946. https://doi.org/10.1038/s41467-022-28639-4 https://www.nature.com/articles/s41467-022-28639-4
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. NPJ Breast Cancer. 2022;8(1):57. https://doi.org/10.1038/s41523-022-00425-x https://pubmed.ncbi.nlm.nih.gov/35501337/
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clin Cancer Res. 2021;27(9):2624-2635. https://doi.org/10.1158/1078-0432.CCR-20-3463https://pubmed.ncbi.nlm.nih.gov/33589432/
A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer. bioRxiv 2021.03.23.436061; https://doi.org/10.1101/2021.03.23.436061 https://www.biorxiv.org/content/10.1101/2021.03.23.436061v1.abstract
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics. 2020;10(10):4515-4529. Published 2020 Mar 15. https://doi.org/10.7150/thno.41453 https://pubmed.ncbi.nlm.nih.gov/32292512/
Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer. 2020;8(2):e001294. https://doi.org/10.1136/jitc-2020-001294 https://pubmed.ncbi.nlm.nih.gov/32948653/
Differential gene expression of tumor-infiltrating CD4+ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology. 2020;9(1):1825178. Published 2020 Sep 30. https://doi.org/10.1080/2162402X.2020.1825178 https://pubmed.ncbi.nlm.nih.gov/33101776/
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S127) in human breast cancers and matching brain metastases. Ther Adv Med Oncol. 2020;12:1758835920946259. https://doi.org/10.1177/1758835920946259 https://pubmed.ncbi.nlm.nih.gov/33014146/
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019;10(1):1741. https://www.ncbi.nlm.nih.gov/pubmed/30988301
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019;5. pii: 124092. https://www.ncbi.nlm.nih.gov/pubmed/30830863
EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel), 2018 ;10(12). pii: E519. https://www.ncbi.nlm.nih.gov/pubmed/30562956
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018; 50(7):968-978. https://www.ncbi.nlm.nih.gov/pubmed/29915430
Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Res Treat, 2018;170(1):179-188. https://www.ncbi.nlm.nih.gov/pubmed/29468485
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res Treat, 2018;167(1):289-301. https://www.ncbi.nlm.nih.gov/pubmed/28889351
Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. American Journal of Human Genetics, 2017;101(2):255-266. https://www.ncbi.nlm.nih.gov/pubmed/28777932
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget, 2016, 13;7(37):60087-60100. https://www.ncbi.nlm.nih.gov/pubmed/27507046
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 2014;3:e100. https://www.ncbi.nlm.nih.gov/pubmed/24752235
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 2014;20(12):3187-97. https://www.ncbi.nlm.nih.gov/pubmed/24838526
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget, 2014;5(10):3145-58. https://www.ncbi.nlm.nih.gov/pubmed/24762669
Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 2014;55(5):772-9. https://www.ncbi.nlm.nih.gov/pubmed/24676755
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine, 2013;54(6):913-21. https://www.ncbi.nlm.nih.gov/pubmed/23564760
All publications at https://www.ncbi.nlm.nih.gov/pubmed/?term=al-ejeh
- 2016 - Certificate of Excellence in Reviewing, Oncology Reports Journal - Spandidos Publications (Athens/Greece)
- 2016 - Commendation Letter for Outstanding Contribution to Institutional Animal Ethics Committee, QIMRB Medical Research Institute (Brisbane, Australia)
- 2016 - Outstanding External Assessor Contribution to NH&MRC Honour Roll 2016, Australian National Health & Medical Research Council (Canberra, Australia)
- 2014 - Commendation Letter for insightful oral presentation as a keynote speaker at the Australian and New Zealand Society of Nuclear Medicine, Australian and New Zealand Society of Nuclear Medicine (ANZSNM, Australia)
- 2008 - Asia-Pacific Frost & Sullivan Technology Innovation Award For APOMAB innovation in Oncaidia Ltd., Frost & Sullivan (Santa Clara, California)
- 2003 - ASMR Young Investigator Award, Australian Society for Medical Research (ASMR, Australia)
Dr. Mahmoud Naas
Research Grant Manager
Phone
66 980 238Office location
Office # 1360 Segment 6, Building 2 HBKU Research Complex
Dr. Mahmoud Naas
Research Grant Manager
Educational Qualifications
PhD
MSc
Entity
Qatar Biomedical Research Institute
Division
Management
Biography
Mahmoud Naas has been in the medical research field and academia for more than 30 years. .
He was previously an associate professor at Qatar University’sCollege of Health Sciences, where he developed and delivered a variety of courses.
As a scientist, Professor Naas’ research activity is an integral part of his academic role; his research has generated several peer reviewed publications, as well as poster presentations at national and international conferences.
PhD
Reading - United Kingdom
1992
MSc
Reading - United Kingdom
1986
BSc
The Higher Institute of Technology, Brack - Libya
1983
- The development of new method for Haemoglobinopathy Screening –all single
- Non-invasive early pregnancy screening for maternal and fetal wellbeing
- such as Preeclampsia
- Ectopic Pregnancy
- Gestational Diabetes and Fetal Aneuploidy T21 Down Syndrome.
- Cancer-Early diagnosis and monitoring.
Associate Professor
Community College Qatar (CCQ), Doha - Qatar
2018 - 2019
Project Manager
Map Sciences Ltd, Bedford - United Kingdom
2016 - 2018
Associate Professor
Qatar University, Doha - Qatar
2013 - 2016
Senior Lecturer
Middlesex University, London _ United Kingdom
2004 - 2013
Tissue Bank Manager
Queen Mary University, London – UK
2001 - 2004
Future Laboratory Medicine: Rapid, Efficient and Affordable Screening for Haemoglobinopathies by MALDI-ToF Mass Spectrometry. Adv Biochem Biotehcnol (in press)
Novel insights into the expression of CGB1 & 2 genes by epithelial cancer cell lines secreting ectopic free hCGβ. Anticancer Research 34:2239-2248
No evidence for the involvement of XMRV or MCV in the pathogenesis of breast cancer British Journal of Cancer 106:1166 – 1170
Human Papilloma Viruses Infections in Sporadic Benign Prostatic Hyperplasia and Prostate Cancer Journal of Pathology 226: S14-
GLI1 induces a basal-like phenotype that confers androgen independence upon LNCaP prostate cancer cells. PLoS One. ;6 (5)
Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development. Cancer Res 65: 9137-9141
- 1997; Research Fellowship; Joint Research Board, St Bartholomew’s Hospital; London – United Kingdom
Dr. Ramesh Elango
Postdoctoral Researcher
Dr. Ramesh Elango
Postdoctoral Researcher
Educational Qualifications
PhD in Biochemistry
MSc in Biochemistry
Entity
Qatar Biomedical Research Institute
Division
Translational Oncology Research Center
Biography
Dr. Ramesh Elango is a Postdoctoral Researcher at Qatar Biomedical Research Institute’s Translational Oncology Research Center. He earned his PhD from Bharathidasan University, India, where he researched the anti-atherogenic effects of epigallocatechin gallate from green tea. His work demonstrated that EGCG protects against oxidative damage, reduces inflammation, and regulates key genes involved in cholesterol metabolism. Dr. Ramesh Elango is an expert in advanced techniques such as CRISPR/Cas9-based functional genomics, RNA sequencing, and the profiling of microRNAs and long noncoding RNAs (lncRNAs).
He later completed postdoctoral studies at King Saud University, Saudi Arabia, where his work led to the discovery of a miRNA-based molecular signature associated with lymph node metastasis in breast cancer. His research focuses on pioneering cancer therapies and identifying novel molecular biomarkers. With over a decade of experience in cancer research, his contributions have been pivotal in identifying therapeutic targets in aggressive cancer subtypes, particularly triple-negative breast cancer (TNBC). He emphasizes the translation of molecular discoveries into clinical applications. Dr. Elango has published over 30 peer-reviewed research articles and book chapters, contributing significantly to the field of oncology.
PhD in Biochemistry
Bharathidasan University, India
2009
MSc in Biochemistry
Periyar University, India
2003
BSc in Biochemistry
Periyar University, India
2001
- Exploring molecular signatures for predicting pathological complete response to Neoadjuvant therapy in breast cancer
- Utilizing transcriptomic profiling for insights into breast cancer diagnosis
- prognosis
- and therapeutic approaches
- Applying CRISPR-Cas9 genomic screens to uncover novel therapeutic vulnerabilities and mechanisms of chemotherapy resistance in breast cancer
- Investigating miRNA and lncRNA signatures in triple-negative breast cancer (TNBC) for understanding treatment resistance and tumorigenicity
Postdoctoral Researcher
Qatar Biomedical Research Institute, Hamad Bin Khalifa University
2019 - Present
Assistant Research Professor
Stem Cell Unit, King Saud University, Saudi Arabia
2016 - 2019
Biotechnology Application Specialist
Asila-Riyadh Company, Saudi Arabia
2012 - 2016
Postdoctoral Researcher
Food Science and Nutrition, King Saud University, Saudi Arabia
2009 - 2012
Elango, R., Vishnubalaji, R., Rashid, S., Al-Sarraf, R., Akhtar, M., Ouararhni, K., & Alajez, N. M. (2024). Long noncoding RNA profiling unveils LINC00960 as an unfavorable prognostic biomarker promoting triple-negative breast cancer progression. Cell Death Discovery, 10(1), 333.
Elango, R., Rashid, S., Vishnubalaji, R., Al-Sarraf, R., Akhtar, M., Ouararhni, K., Decock, J., Albagha, O. M. E., & Alajez, N. M. (2023). Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks. Cell Death & Disease, 14(1), 415.
Elango, R., Vishnubalaji, R., Shaath, H., & Alajez, N. M. (2021). Transcriptional alterations of protein-coding and noncoding RNAs in triple-negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell International.
Elango, R., Vishnubalaji, R., Shaath, H., & Alajez, N. M. (2021). Molecular subtyping and functional validation of TTK, TPX2, UBE2C, and LRP8 in sensitivity of TNBC to paclitaxel. Molecular Therapy - Methods & Clinical Development, 20, 601–614.
Elango, R., Alsaleh, K. A., Vishnubalaji, R., Manikandan, M., Ali, A. M., Abd El-Aziz, N., Altheyab, A., Al-Rikabi, A., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2020). MicroRNA expression profiling on paired primary and lymph node metastatic breast cancer revealed a distinct microRNA profile associated with LNM. Frontiers in Oncology.
Dr. Afif Ben Mahmoud
Senior Research Associate
Dr. Afif Ben Mahmoud
Senior Research Associate
Educational Qualifications
PhD (Molecular and Human Genetics)
MSc in Genetics and Biodiversity
Entity
Qatar Biomedical Research Institute
Division
Neurological Disorders Research Center
Biography
Dr. Afif Ben Mahmoud is an accomplished geneticist and genome data analyst with extensive expertise in human molecular genetics. He earned an engineering degree in agriculture and animal production, a master's in genetics and biodiversity, and a PhD in molecular and human genetics. With over 12 years of experience in research and academia, Dr. Ben-Mahmoud has dedicated his work to elucidating cellular and molecular mechanisms underlying human genetic diseases, focusing on identifying disease genes and mutations responsible for rare recessive disorders, particularly in Arab populations.
His professional contributions in genetic pathology span from phenotypic and genotypic characterization of patients with monogenic diseases to functional studies aimed at demonstrating the pathogenicity of disease-causing novel genes and gene variations. He has also led numerous projects to decode rare human monogenic diseases, significantly advancing the field.
Dr. Afif Ben Mahmoud’s notable accomplishments include the first functional analysis of B3GALTL in Tunisian patients with Peters Plus Syndrome, the identification of MAST1 as a novel intellectual disability gene, and confirming the role of B3GALT6 in Al-Gazali Syndrome. Additionally, he has identified 16 autosomal dominant candidate genes in syndromic neurodevelopmental disorders and new candidate loci for intellectual disability and Kallmann syndrome. Dr. Ben-Mahmoud has published 25 high-quality articles in renowned international peer-reviewed journals, with over 500 citations and an h-index of 14.
PhD (Molecular and Human Genetics)
Sfax University, Tunisia
2015
MSc in Genetics and Biodiversity
Monastir University, Tunisia
2009
Engineering in Agriculture and Animal Production
Carthage University, Tunisia
2007
- Identification of novel disease genes and their pathogenic variants in autism and human monogenic diseases in Qatar.
- Investigation of genetic diversity and recessive disorders in Arab populations in Qatar.
- Functional validation of novel genes associated with intellectual disability and autism spectrum disorder in the Qatari population.
- Elucidation of cellular and molecular mechanisms in syndromic neurodevelopmental disorders in Qatar.
Senior Research Associate
Qatar Biomedical Research Institute, Hamad Bin Khalifa University
2019 - present
PostDoc Researcher
College of Medicine & Health Sciences, United Arab Emirates University, UAE
2016 - 2018
Ben-Mahmoud, A., Gupta, V., Kim, C.-H., Layman, L. C., & Kim, H.-G. (2023). Digenic or oligogenic mutations in presumed monogenic disorders: A review. Journal of Genetic Medicine, 20(1), 15–24.
- 2018; Researchers at UAEU develop cell lines with gene-editing technology CRISPR-Cas9 used to understand diseases
Suad Al-Dosari
Research Quality Assurance Manager
Phone
44 546 072Office location
Research Complex ,B2, Level 1,Ofiice no 1475
Suad Al-Dosari
Research Quality Assurance Manager
Educational Qualifications
B.Sc. degree in Medical Technology
Entity
Qatar Biomedical Research Institute
Division
Management
Biography
Suad Salem Al-Dosari obtained her Bachelor of Science in Medical Technology from Petra University in Amman, Jordan. She began her career at Hamad Medical Corporation in 2000, as a senior lab technologist at the Blood Bank. In 2014, she joined QBRI as Senior Research Associate with the Compliance Office. With 19 years of experience in both technical laboratory work and compliance work, she is currently a Quality Assurance Manager at QBRI.
B.Sc. degree in Medical Technology
Petra University in Amman-Jordan
2000
Senior Laboratories Technologist HMC
July 2000 - Sep 2009
Reserach Associate
Shafallah Medical Genetics Center
2010 - 2014
Senior Reserach associate
April 2014 - July2019
Qaulity Assurance Manager
Aug 2019 - Present
Dr. Yongsoo Park
Senior Scientist
Associate Professor
Dr. Yongsoo Park
Senior Scientist
Associate Professor
Educational Qualifications
PhD in Molecular Neurobiology
BS in Life Science
Entity
Qatar Biomedical Research Institute
College of Health and Life Sciences
Biography
Dr. Yongsoo Park is an Associate Professor at the College of Health and Life Sciences and a Senior Scientist at Qatar Biomedical Research Institute. He received PhD in investigating exocytosis and plasticity of vesicle fusion at the Pohang University of Science and Technology (POSTECH), South Korea.
After completing his PhD degree in 2009, he worked as a Postdoctoral Researcher at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany, being trained by a mentor Prof. Reinhard Jahn, a world-renowned scientist by his pioneering research into fusion and neurotransmitter release. In 2015, he was appointed as an Assistant Professor at the Izmir International Biomedicine and Genome Institute where he joined the Department of Molecular Biology and Genetics at the Koç University, Istanbul, Turkey.
In 2019 Dr. Park moved to the Qatar Biomedical Research Institute (QBRI) and is coaffiliated at the College of Health and Life Sciences aiming to model neurological disease with patient-specific hiPSC-derived neurons. His lab focuses on extracellular vesicle biomarkers for autism spectrum disorder (ASD), Parkinson’s disease, and Alzheimer's disease. He also studies lipid dysregulation in neurological disease conditions with a focus on calcium signaling and vesicle fusion. By applying interdisciplinary approaches, his team investigates molecular mechanisms of neurological disorders and the development of therapeutics.
PhD in Molecular Neurobiology
Pohang University of Science and Technology (POSTECH), South Korea
2002 - 2009
BS in Life Science
Handong Global University, South Korea
1996 - 2001
- Exosome and extracellular vesicle (EV) biomarkers for neurological disorders including autism spectrum disorder (ASD).
- Use of neuronal differentiation of human induced pluripotent stem cells (hiPSC) as a disease model of ASD
- Alzheimer's disease
- and Parkinson’s disease.
- Lipid dysregulation in neurological disease condition with a focus on vesicle fusion.
- Molecular mechanisms of neuronal degeneration in neurological disorders and microRNA exocytosis in health and disease.
Senior Scientist
Qatar Biomedical Research Institute, Hamad Bin Khalifa University
2024 - Present
Associate Professor
College of Health and Life Sciences, Hamad Bin Khalifa University
2024 - Present
Scientist
Qatar Biomedical Research Institute, Hamad Bin Khalifa University
2019 - 2024
Assistant Professor
College of Health and Life Sciences, Hamad Bin Khalifa University
2019 - 2024
Assistant Professor
Molecular Biology and Genetics, Koç University, Turkey
2017 - 2019
Assistant Professor
Izmir International Biomedicine and Genome Institute, Turkey
2015 - 2017
Postdoctoral Researcher
Max Planck Institute for Biophysical Chemistry, Germany
2009 - 2015
Ali Moussa, H. Y., Shin, K. C., & Park, Y. (2025). Ca2+/calmodulin and protein kinase C (PKC) reverse the vesicle fusion arrest by unmasking PIP2. Science Advances.
Shin, K. C., Ali Moussa, H. Y., & Park, Y. (2024). Cholesterol imbalance and neurotransmission defects in neurodegeneration. Experimental & Molecular Medicine, 56(8), 1685–1690.
Ali Moussa, H. Y., Shin, K. C., Ponraj, J., Park, S. H., Lee, O. S., Mansour, S., & Park, Y. (2024). PIP2 is an electrostatic catalyst for vesicle fusion by lowering the hydration energy: Arresting vesicle fusion by masking PIP2. ACS Nano, 18(20), 12737–12748.
Shin, K. C., Ali, G., Ali Moussa, H. Y., Gupta, V., de la Fuente, A., Kim, H. G., Stanton, L. W., & Park, Y. (2023). Deletion of TRPC6, an autism risk gene, induces hyperexcitability in cortical neurons derived from human pluripotent stem cells. Molecular Neurobiology, 60(12), 7297–7308.
Ali Moussa, H. Y., Shin, K. C., Ponraj, J., Kim, S. J., Ryu, J. K., Mansour, S., & Park, Y. (2023). Requirement of cholesterol for calcium-dependent vesicle fusion by strengthening synaptotagmin-1-induced membrane bending. Advanced Science, 10(15), e2206823.
Complete Publication Listing(s): NCBI
- Member, International Advisory Board of the International Symposium on Chromaffin Cell Biology (ISCCB) (2023).
- Best faculty/researcher poster award, second place, the 1st HBKU Research Day (7.Sep.2022).
- Member, EMBO Young Investigator Programme (YIP) as an EMBO Installation Grantee (2016-2020).
- Science Academy’s Young Scientist Awards Program (BAGEP), Bilim Akademisi, Turkey (27. 04. 2017).
- Research fellowship for post-doctoral researcher, Alexander von Humboldt Foundation (2010 – 2012).
Dr. Maria teresa B Alonso
Postdoc
Dr. Maria teresa B Alonso
Postdoc
Educational Qualifications
PhD
Entity
College of Health and Life Sciences
PhD
Universidad de Navarra, Pamplona, Spain
1999
- Cancer Metabolism
- Transcriptional Regulation
- Lipid Metabolism
- Diabetes and Metabolic Disease
Research Fellow
UCD Conway Institute, School of Medicine and Medical Science, University College Dublin
2009 - 2018
Post-doctoral fellow
Ludwig Institute for Cancer Research Uppsala, Sweden
2002 - 2009
Post-doctoral fellow
University of Missouri-Kansas City, Kansas City, Missouri, USA
1999 - 2002
The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth. Cell Cycle. 15(20):2753-65.
The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degradation. Proc. Natl. Acad. Sci. U.S.A. 107, 11817–11822.
A phosphorylation cascade controls the degradation of active SREBP1. J. Biol. Chem. 284(9): 5885-5895.
CDK1/Cyclin B-mediated phosphorylation stabilizes SREBP1 during mitosis. Cell Cycle. 5(15):1708-18.
Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J. Biol. Chem. 281(35): 25278-86.
Hyperphosphorylation regulates the activity of SREBP1 during mitosis. Proc. Natl. Acad. Sci. U.S.A. 102(33):11681-6
Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 1(6):379-91. #These authors contributed equally to this work.
Dr. Ehsan Pourkarimi Daryakenari
Assistant Professor
Dr. Ehsan Pourkarimi Daryakenari
Assistant Professor
Educational Qualifications
Ph.D in Genetics
M.Sc. in Genetics
Entity
College of Health and Life Sciences
Biography
Dr. Ehsan Pourkarimi obtained his undergraduate degree from Eötvös Loránd University (ELTE) in Budapest, Hungary.
After receiving a Cancer Research Fellowship, he moved to the United Kingdom to join Professor Anton Gartner at the Wellcome Trust Center for Gene Regulation and Expression at the University of Dundee. During his post-doctoral work, Dr. Pourkarimi focused his research on understanding the effect of chromatin modifiers in cellular response during acute stress conditions. He then moved to New York City and worked as a Research Associate in the lab of Dr. Iestyn Whitehouse at Memorial Sloan Kettering Cancer Center where he studied DNA replication.
Ph.D in Genetics
Wellcome Trust Center For Gene Regulation and Expression, University of Dundee, United Kingdom
2007 - 2012
M.Sc. in Genetics
Eötvös Loránd University, Budapest, Hungary
2001 - 2007
- Transgenerational Inheritance of Epigenetic Information
- Establishing an all-in-one Toolkit for Epigenome Editing
- Understanding the Role of Histone Modification in DNA Damage-Induced Apoptosis
Research Associate
Memorial Sloan Kettering Cancer Center, New York, USA
2016 - 2018
Post Doctoral Fellow
Memorial Sloan Kettering Cancer Center, New York, USA
2013 - 2016
Post Doctoral Fellow
University of Dundee, UK
2012 - 2013
Ehsan Pourkarimi, James M Bellush, Iestyn Whitehouse
Vikram Narayan, Tony Ly, Ehsan Pourkarimi, Alejandro Brenes Murillo, Anton Gartner, Angus I. Lamond, and Cynthia Kenyon
Mark Larance*, Ehsan Pourkarimi*, Bin Wang, Alejandro Brenes Murillo, Robert Kent, Angus I. Lamond and Anton Gartner
Federico Pelisch, Remi Sonneville, Ehsan Pourkarimi, Ana Agostinho, J. Julian Blow, Anton Gartner & Ronald T. Hay
Luca Fancsalszky, Eszter Monostori, Zsolt Farkas, Ehsan Pourkarimi, Neda Masoudi, Balázs Hargitai, Maja Herak Bosnar, Martina Deželjin, Annamária Zsákai, Tibor Vellai, Anil Mehta, Krisztina Takács-Vellai
Alper Akay , Ashley Craig , Nicolas Lehrbach , Mark Larance , Ehsan Pourkarimi , Jane E. Wright , Angus Lamond , Eric Miska and Anton Gartner
Neda Masoudi*, Luca Fancsalszky*, Ehsan Pourkarimi*, Tibor Vellai, Anita Alexa, Attila Reményi, Anton Gartner, Anil Mehta, Krisztina Takács-Vellai.
Ehsan Pourkarimi & Anton Gartner
Ehsan Pourkarimi, Sebastian Greiss & Anton Gartner
Sarah L. Murdoch, Katharina Trunk, Grant English, Maximilian J. Fritsch, Ehsan Pourkarimi, Sarah J. Coulthurst
Mark Larance, Aymeric P Bailly, Ehsan Pourkarimi, Ronald T Hay, Grant Buchanan, Sarah Coulthurst, Dimitris P Xirodimas, Anton Gartner & Angus I Lamond
- Best science image award. Visions of discovery.
- Cancer research UK PhD scholarships, UK
- Overseas Research Students Awards Scheme (ORSAS) award, UK
Dr. Lina Majed
Assistant Professor
Dr. Lina Majed
Assistant Professor
Educational Qualifications
PhD in Human Movement Science
MSc in Motor Control and Perception
Entity
College of Health and Life Sciences
Biography
Dr. Lina Majed is an Assistant Professor at the College of Health and Life Sciences at Hamad Bin Khalifa University. She obtained her Master's and PhD degrees in Human Movement Science from Paris-Saclay University. Her research area focuses on a multidisciplinary approach to preferred motor behaviors. She is currently examining characteristics of gait patterns as related to health and the influences of culture and environments on gait.
She has a keen interest in understanding the interplays between physical activity, preferred motor behaviors, health, and well-being. Dr. Lina is the leader of the national task force on the Qatar ‘Active Healthy Kids Report Card’ (part of a Global Alliance) in collaboration with several governmental and academic institutions. She has contributed to the National Physical Activity Guidelines for Qatar. With more than 10 years of academic experience, she has published several high-impact journal publications with direct relevance to Qatar and its population's health.
PhD in Human Movement Science
Paris-Saclay University, France
2013
MSc in Motor Control and Perception
Paris-Saclay University, France
2008
BA in Physical Education
University of Balamand, Lebanon
2006
- Preferred motor behaviors
- Gait analysis
- Physical activity and health
- Exercise and fitness
Assistant Professor
College of Health and Life Sciences, Hamad Bin Khalifa University
2023 - Present
Associate Professor of Exercise and Fitness
College of Education, Qatar University
2021 - 2023
Adjunct Faculty
College of Health and Life Sciences, Hamad Bin Khalifa University
2021
Visiting Faculty
College of Health and Life Sciences, Hamad Bin Khalifa University
2020
Assistant Professor of Exercise and Fitness
College of Health and Life Sciences, Qatar University
2013 - 2021
Complete Publication Listing(s): Google Scholar
Dr. Ibrahim Mohamed Zain Abdelwahid
Acting Dean of the College of Humanities and Social Sciences
Dr. Ibrahim Mohamed Zain Abdelwahid
Acting Dean of the College of Humanities and Social Sciences
Educational Qualifications
PhD in Religion
MA in Religion
Entity
College of Humanities and Social Sciences
Program
Master of Arts in Contemporary Islamic Studies
Division
Islamic Studies
Biography
Dr. Ibrahim Zain is a Professor of Islamic Studies and Comparative Religion at the College of Islamic Studies, Hamad Bin Khalifa University (Doha, Qatar). His various academic postings include Dean of the Kulliyyah (Faculty) of Islamic Revealed Knowledge and Human Sciences (KIRKHS) and Dean of the International Institute of Islamic Thought and Civilization (ISTAC) at the International Islamic University Malaysia (IIUM). He writes extensively on the history of religions and reform of Islamic education and has authored over 50 publications, including several books, in English and Arabic. Dr. Zain is a leading scholar on the study of the Covenants of the Prophet Muḥammad.
PhD in Religion
Temple University, Pennsylvania
1989
MA in Religion
Temple University, Pennsylvania
1986
MA in Philosophy
University of Khartoum
1984
BA (Hons.) in Philosophy
University of Khartoum
1980
- The Covenants of the Prophet Muhammad and Relevancy to the Reconstruction of the Sīra and Inter-religious Dialogue
- Al-Fitna al-Kubrā (i.e. the First Civil War) and its Implications on Muslim Historiography
- Teaching and Learning Islam in Contemporary Muslim Institutions of Higher Learning
- Religion and Art in Tayeb Salih Novels
- Religion
- Legality and the State: the Sudanese Experience
- Maqāṣid al-Sharī‘a and Codification of Islamic Rulings
Professor of Islamic Studies and Comparative Religion
CIS, HBKU
Aug 2016 – Present
Dean, Kuliyyah of Islamic Revealed Knowledge & Human Sciences
International Institute of Islamic Thought and Civilization (ISTAC), Malaysia
Jun 2013 – Jun 2016
Dean
International Institute of Islamic Thought and Civilization (ISTAC), Malaysia
Jun 2007 – Oct 2010
Deputy Dean, Student Affairs, Centre for Postgraduate Studies
International Islamic University in Malaysia (IIUM)
Jul 2004 – Jun 2005
Professor
International Islamic University in Malaysia (IIUM)
Dec 2003 – Jun 2016
Deputy Dean, Academic Affairs, Centre for Postgraduate Studies
International Islamic University in Malaysia (IIUM)
Aug 2003 – Jun 2004, Jul 2005 – Jul 2006
Deputy Dean, Academic Affairs
International Islamic University in Malaysia (IIUM)
Jul 1999 – Jul 2001
Head, Department of Fiqh and Usul Al Fiqh
International Islamic University in Malaysia (IIUM)
Jul 1998 – Jul 1999
Associate Professor
International Islamic University in Malaysia (IIUM)
Oct 1997 – Dec 2003
Head, Department of Islamic Revealed Knowledge & Human Sciences
International Islamic University in Malaysia (IIUM)
May 1996 – Dec 1996
Deputy Dean Pre-sessional Programme
International Islamic University in Malaysia (IIUM)
May 1995 – Apr 1996
Coordinator, Diploma of Islamic Studies, and Usul Din & Comparative Religion
International Islamic University in Malaysia (IIUM)
May 1994 – Apr 1995
Assistant Professor
International Islamic University in Malaysia (IIUM)
May 1993 – Oct 1997
Head, Department of Islamic Studies
University of Khartoum
1992 – 1993
Assistant Professor
University of Khartoum
Sep 1989 – May 1993
Teaching Assistant
University of Khartoum
Jan 1981 – Aug 1989
BOOKS
مركز التنوير المعرفي ، الخرطوم ، 2010.
Kuala Lampur: IIUM Press.
Khartoum: Markaz al-Tanwīr al-Ma‘rifī.
Khartoum: Kitāb al-Khartoum al-Jadidah.
BOOK CHAPTERS
In El-Mesawi, M. E. (Ed.), Maqāṣid al-Sahrī‘ah: Explorations and Implications.Kuala Lumpur: Islamic Book Trust.
In Kamaruddin, Z. & Moten, A. R. (Eds.), IIUM: The Premier Global Islamic University. Kuala Lumpur: IIUM Press.
In Yusuf, I. (Ed.), Islam and Knowledge: The Concept of Religion In Islamic Thought. London: I.B. Tauris.
In Ahad, A., & Sarif, S. M. (Eds.), Spirituality in Management From Islamic Perspectives. Kuala Lumpur: IIUM Press.
في كتاب هذا هو المكان، تحرير د. إيمان عباس. مركز عبد الكريم مرغني، أم درمان، 2010.
In Young, S. B., & Al-Ahsan, A. (Eds.), Guidance For Good Governance: Explorations In Qur'anic, Scientific And Cross-Cultural Approaches. Kuala Lampur: IIUM Press and Caux Round Table.
In Faessel, V. A. (Ed.), Salvation and Pluralism In Monotheistic Religions. Kyoto: CISMOR.
In Pathmanathan, M., & Hass, R. (Eds.), Political Culture: The Challenge of Modernization. Kuala Lumpur: Friedrich Nauman Foundation and Center of Policy Sciences.
In Pathmanathan, M., & Hass, R. (Eds.), Civic Education and the Role of Religion. Kuala Lumpur: Friedrich Nauman Foundation and Center of Policy Sciences.
JOURNAL ARTICLES
Intellectual Discourse, 24 (2). 217-243.
American Journal of Islamic Social Sciences, 61 (137). 1-18.
At-Tajdid, 20 (39).
Islamiyat al-Ma`rifat: Journal of Contemporary Islamic Thought, 20 (79). 125-138.
Revelation and Science, 4 (2).
Intellectual Discourse, 22 (1). 53-71.
Al-Shajarah, 19 (1). 85-130.
Al-Tajdid, 17 (33). 11-49.
Intellectual Discourse. 16 (2). 187-208.